CO7151491A2 - Método para la identificación del origen de un cancer de origen primario desconocido - Google Patents

Método para la identificación del origen de un cancer de origen primario desconocido

Info

Publication number
CO7151491A2
CO7151491A2 CO14270873A CO14270873A CO7151491A2 CO 7151491 A2 CO7151491 A2 CO 7151491A2 CO 14270873 A CO14270873 A CO 14270873A CO 14270873 A CO14270873 A CO 14270873A CO 7151491 A2 CO7151491 A2 CO 7151491A2
Authority
CO
Colombia
Prior art keywords
origin
cpd
methods
unknown primary
cancer
Prior art date
Application number
CO14270873A
Other languages
English (en)
Inventor
Badosa Manel Esteller
Original Assignee
Fundacio Inst D Investigació Biomédica De Bellvitge Idibell
Fundacio Institució Catalana De Recerca I Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst D Investigació Biomédica De Bellvitge Idibell, Fundacio Institució Catalana De Recerca I Estudis Avancats filed Critical Fundacio Inst D Investigació Biomédica De Bellvitge Idibell
Publication of CO7151491A2 publication Critical patent/CO7151491A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se refiere a métodos y reactivos para la identificación del origen deun carcinoma de origen primario desconocido (CPD) basada en la determinación delperfil de metilación en el genoma del CPD. La invención se refiere también a métodospara seleccionar una terapia adecuada para un paciente que padece un CPD así como amétodos para la medicina personalizada de pacientes que adecen un CPD basándose enel uso de un tratamiento que sea adecuado para el tumor primario del que deriva elCPD. La invención también se refiere a kits que comprenden reactivos adecuados pararealizar los métodos anteriores así como a sistemas y programas informáticos que sepueden usar para implementar los métodos de la invención.
CO14270873A 2012-05-24 2014-12-10 Método para la identificación del origen de un cancer de origen primario desconocido CO7151491A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/059687 WO2013174432A1 (en) 2012-05-24 2012-05-24 Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis

Publications (1)

Publication Number Publication Date
CO7151491A2 true CO7151491A2 (es) 2014-12-29

Family

ID=46168453

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14270873A CO7151491A2 (es) 2012-05-24 2014-12-10 Método para la identificación del origen de un cancer de origen primario desconocido

Country Status (6)

Country Link
US (1) US10233503B2 (es)
AU (1) AU2012380717B2 (es)
CA (1) CA2874407A1 (es)
CO (1) CO7151491A2 (es)
MX (1) MX2014014356A (es)
WO (1) WO2013174432A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3889272A1 (en) 2014-07-18 2021-10-06 The Chinese University of Hong Kong Methylation pattern analysis of tissues in dna mixture
US9984201B2 (en) * 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
WO2017106481A1 (en) * 2015-12-17 2017-06-22 Illumina, Inc. Distinguishing methylation levels in complex biological samples
US9396251B1 (en) * 2016-01-07 2016-07-19 International Business Machines Corporation Detecting and tracking virtual containers
TWI648403B (zh) * 2016-07-29 2019-01-21 臺北醫學大學 婦科腫瘤的診斷方法
CA3034903A1 (en) * 2016-09-02 2018-03-08 Mayo Foundation For Medical Education And Research Detecting hepatocellular carcinoma
AU2017369018B2 (en) 2016-11-30 2021-02-25 The Chinese University Of Hong Kong Analysis of cell-free DNA in urine and other samples
DK3592867T3 (da) * 2017-03-10 2022-10-17 Self Screen Bv Methyleringsklassifikator til påvisning af hpv-inducerede, invasive cancere, ikke-hpv-inducerede, gynækologiske og anogenitale cancere og højmaligne forløberlæsioner herfor
CN108319969B (zh) * 2018-01-12 2021-06-22 复旦大学 基于稀疏表示框架的脑胶质瘤生存期预测方法和系统
EP3765637A1 (en) 2018-03-13 2021-01-20 Grail, Inc. Anomalous fragment detection and classification
CN109182518A (zh) * 2018-09-12 2019-01-11 黄映辉 基于焦磷酸测序技术的gstp1基因启动子甲基化检测方法
AU2019404445A1 (en) * 2018-12-21 2021-06-24 Grail, Llc Anomalous fragment detection and classification
EP3899953A1 (en) * 2018-12-21 2021-10-27 Grail, Inc. Source of origin deconvolution based on methylation fragments in cell-free-dna samples
CA3127329A1 (en) * 2019-01-24 2020-07-30 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
US11773450B2 (en) 2019-04-03 2023-10-03 Grail, Llc Methylation-based false positive duplicate marking reduction
CN110257513B (zh) * 2019-05-28 2020-08-04 深圳市人民医院 一种用于乳腺癌早期筛查的检测试剂、试剂盒及检测试剂的应用
CN114222588A (zh) 2019-08-12 2022-03-22 雷杰纳荣制药公司 巨噬细胞刺激1受体(mst1r)变体及其用途
WO2021029462A1 (ko) * 2019-08-13 2021-02-18 한국식품연구원 고혈압 또는 비만의 예측 또는 진단용 조성물
CN114438201A (zh) * 2020-11-05 2022-05-06 复旦大学附属华山医院 一种肿瘤标志物组合及其应用
WO2024112741A1 (en) * 2022-11-23 2024-05-30 Salk Institute For Biological Studies Dna methylation barcodes for identifying brain cells

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943A (en) 1847-01-26 Harness-buckle
US533A (en) 1837-12-26 Truss for hermta
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5525462A (en) 1991-05-02 1996-06-11 Toyo Boseki Kabushiki Kaisha Nucleic acid sequence amplification method, detection method, and reagent kit therefor
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
GB9517955D0 (en) 1995-07-25 1995-11-08 Univ Strathclyde Nucleotide sequence detection and analysis
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5858665A (en) 1996-07-25 1999-01-12 Navix, Inc. Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification
AU4667297A (en) 1996-10-04 1998-04-24 Chronix Biomedical, Inc. Diagnostic detection of nucleic acids
JPH10253632A (ja) 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6292169B1 (en) 1998-02-13 2001-09-18 Kabushiki Kaisha Toshiba Information input apparatus
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US6780591B2 (en) 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
JP3813818B2 (ja) 1998-05-01 2006-08-23 アリゾナ ボード オブ リージェンツ オリゴヌクレオチドおよびｄｎａ分子のヌクレオチド配列の決定方法
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US7700324B1 (en) 1998-11-03 2010-04-20 The Johns Hopkins University School Of Medicine Methylated CpG island amplification (MCA)
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
AU2003212878A1 (en) 2002-01-30 2003-09-02 Epigenomics Ag Identification of cell differentiation states based on methylation patterns
US8003317B2 (en) 2003-07-31 2011-08-23 Sequenom, Inc. Methods for high level multiplexed polymerase chain reactions and homogeneous mass extension reactions
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
JP2005328709A (ja) 2004-05-18 2005-12-02 Toyobo Co Ltd 高速ｄｎａポリメラーゼを用いた高速ｐｃｒ
WO2006002344A1 (en) * 2004-06-23 2006-01-05 Epigenomics Ag Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders
US7643818B2 (en) 2004-11-22 2010-01-05 Seven Networks, Inc. E-mail messaging to/from a mobile terminal
US9074013B2 (en) 2004-11-29 2015-07-07 Sequenom, Inc. Means and methods for detecting methylated DNA
WO2007035690A2 (en) 2005-09-19 2007-03-29 Veridex, Llc Methods for diagnosing pancreatic cancer
WO2007039234A2 (en) * 2005-09-29 2007-04-12 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with tissue classification
GB0700374D0 (en) 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
US8911937B2 (en) 2007-07-19 2014-12-16 Brainreader Aps Method for detecting methylation status by using methylation-independent primers
WO2009021141A1 (en) 2007-08-07 2009-02-12 The Johns Hopkins University Comprehensive high throughput arrays for relative methylation
EP2053131A1 (en) 2007-10-19 2009-04-29 Ludwig-Maximilians-Universität München Method for determining methylation at deoxycytosine residues
US20110028333A1 (en) * 2009-05-01 2011-02-03 Brown University Diagnosing, prognosing, and early detection of cancers by dna methylation profiling

Also Published As

Publication number Publication date
MX2014014356A (es) 2015-07-06
CA2874407A1 (en) 2013-11-28
WO2013174432A1 (en) 2013-11-28
AU2012380717A1 (en) 2015-01-15
AU2012380717B2 (en) 2018-08-16
US10233503B2 (en) 2019-03-19
US20160017430A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
CL2015002807A1 (es) Terapia de combinación
AR102345A1 (es) Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfr
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
CR20120406A (es) Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BR112016024332A2 (pt) métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
SV2017005459A (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
MX351945B (es) Mutantes c-raf que confieren resistencia a inhibidores raf.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
PH12014502219A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor